U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
QS-21 is a purified soapbark tree (Quillaja saponaria) extract that enhances the ability of the immune system to respond to vaccine antigens. QS-21 is a promising adjuvant candidate for use in humans due to the ease of purification, its improved safety profile, and its ability to enhance cellular and humoral immunogenicity. The mechanism of action of QS-21 was speculated to be similar to QA, forming complexes with cholesterol that intercalate into the cell membrane lipids. This intercalation creates pores in the membrane to accelerate the uptake of a co-delivered antigen by the antigen presenting cells. Multiple clinical trials using QS-21 as an adjuvant, demonstrated satisfactory safety profiles and enhanced immunogenicity in immunocompromised volunteers

Originator

Sources: Journal of Immunology (1991), 146, (2), 431-7.

Approval Year

PubMed

PubMed

TitleDatePubMed
Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer.
2011 Apr
Patents

Patents

Sample Use Guides

100 microg five injections each during weeks 1, 2, 3, 7, and 19.
Route of Administration: Other
Substance Class Mixture
Created
by admin
on Sat Dec 16 14:42:55 GMT 2023
Edited
by admin
on Sat Dec 16 14:42:55 GMT 2023
Record UNII
61H83WZX3U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
QUILLAJA SAPONIN (QS-21)
Common Name English
QS-21
Preferred Name English
AS01 COMPONENT QS-21
Common Name English
Purified Quillaja Saponin
Common Name English
AS01E COMPONENT QS-21
Common Name English
QS 21 [WHO-DD]
Common Name English
QS21
Code English
STIMULON
Brand Name English
ALFQ component QS21
Common Name English
QS-21 ADJUVANT
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C2554
Created by admin on Sat Dec 16 14:42:56 GMT 2023 , Edited by admin on Sat Dec 16 14:42:56 GMT 2023
Code System Code Type Description
DAILYMED
61H83WZX3U
Created by admin on Sat Dec 16 14:42:56 GMT 2023 , Edited by admin on Sat Dec 16 14:42:56 GMT 2023
PRIMARY
NCI_THESAURUS
C1478
Created by admin on Sat Dec 16 14:42:56 GMT 2023 , Edited by admin on Sat Dec 16 14:42:56 GMT 2023
PRIMARY NCIT
FDA UNII
61H83WZX3U
Created by admin on Sat Dec 16 14:42:56 GMT 2023 , Edited by admin on Sat Dec 16 14:42:56 GMT 2023
PRIMARY
DRUG BANK
DB05400
Created by admin on Sat Dec 16 14:42:56 GMT 2023 , Edited by admin on Sat Dec 16 14:42:56 GMT 2023
PRIMARY
EVMPD
SUB20573
Created by admin on Sat Dec 16 14:42:56 GMT 2023 , Edited by admin on Sat Dec 16 14:42:56 GMT 2023
PRIMARY
RXCUI
2002417
Created by admin on Sat Dec 16 14:42:56 GMT 2023 , Edited by admin on Sat Dec 16 14:42:56 GMT 2023
PRIMARY
All of the following components must be present:
Related Record Type Details
TARGET -> AGONIST
Related Record Type Details
ACTIVE MOIETY
Definition References